.

Pharmaceutical Business Intelligence

  • Anticipate P&T budget requirements
  • Evaluate market entry opportunities
  • Find generic sources and suppliers
  • Predict branded drug patent expiration

► Plans and Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

DrugPatentWatch Database Preview

Details for Patent: 6,372,778

« Back to Dashboard

Details for Patent: 6,372,778

Title: Sulfonamide inhibitors of aspartyl protease
Abstract:The present invention relates to a novel class of sulfonamides which are aspartyl protease inhibitors. In one embodiment, this invention relates to a novel class of HIV aspartyl protease inhibitors characterized by specific structural and physicochemical features. This invention also relates to pharmaceutical compositions comprising these compounds. The compounds and pharmaceutical compositions of this invention are particularly well suited for inhibiting HIV-1 and HIV-2 protease activity and consequently, may be advantageously used as anti-viral agents against the HIV-1 and HIV-2 viruses. This invention also relates to methods for inhibiting the activity of HIV aspartyl protease using the compounds of this invention and methods for screening compounds for anti-HIV activity.
Inventor(s): Tung; Roger D. (Arlington, MA), Murcko; Mark A. (Holliston, MA), Bhisetti; Govinda R. (Lexington, MA)
Assignee: Vertex Pharmaceuticals, Incorporated (Cambridge, MA)
Filing Date:Jun 07, 1995
Application Number:08/484,326
Claims:1. A compound of formula I: ##STR611##

wherein:

A is selected from the group consisting of Ht; --R.sup.1 --Ht; --R.sup.1 --C.sub.1 -C.sub.6 alkyl substituted with Ht or --O--Ht and optionally substituted with one additional substituent selected from the group consisting of hydroxy, C.sub.1 -C.sub.4 alkoxy, Ht, --O--Ht, --NR.sup.2 --CO--N(R.sup.2) (R.sup.2) and --CO--N(R.sup.2) (R.sup.2); and --R.sup.1 --C.sub.2 -C.sub.6 alkenyl substituted with Ht or --O--Ht and optionally substituted with one additional substituent selected from the group consisting of hydroxy, C.sub.1 -C.sub.4 alkoxy, Ht, --O--Ht, --NR.sup.2 --CO--N(R.sup.2) (R.sup.2) and --CO--N(R.sup.2) (R.sup.2);

each R.sup.1 is independently selected from the group consisting of --C(O)--, --S(O).sub.2 --, --C(O)--C(O)--, --O--C(O)--, --O--S(O).sub.2, --NR.sup.2 --S(O).sub.2 --, --NR.sup.2 --C(O)-- and --NR.sup.2 --C(O)--C(O)--;

each Ht is a 5-membered nitrogen-containing saturated or unsaturated heterocycle, optionally containing one additional heteroatom selected from N or O, wherein said heterocycle is optionally benzofused; and wherein any member of said Ht is optionally substituted with one to two substituents independently selected from the group consisting of oxo, --OR.sup.2, --R.sup.2, --N(R.sup.2) (R.sup.2), --R.sup.2 --OH, --CN, --CO.sub.2 R.sup.2, --C(O)--N(R.sup.2) (R.sup.2), --S(O).sub.2 --N(R.sup.2) (R.sup.2), --N(R.sup.2)--C(O)--R.sub.2, --C(O)--R.sup.2, --S(O).sub.n --R.sup.2, --OCF.sub.3, --S(O).sub.n --R.sup.7, methylenedioxy, --N(R.sup.2)--S(O).sub.2 (R.sup.2), halo, --CF.sub.3, --NO.sub.2, R.sup.7 and --O--R.sup.7 ;

each R.sup.2 is independently selected from the group consisting of H and C.sub.1 -C.sub.3 alkyl optionally substituted with R.sup.7 ; with the proviso that when R.sup.2 is C.sub.1 -C.sub.3 alkyl substituted with R.sup.7, said R.sup.7 may not be substituted with an R.sup.7 -containing moiety;

B, when present, is --N(R.sup.2)--C(R.sup.3) (R.sup.3)--C(O)--;

x is 0 or 1;

each R.sup.3 is independently selected from the group consisting of H, Ht, C.sub.1 -C.sub.6 alkyl, C.sub.2 -C.sub.6 alkenyl, C.sub.3 -C.sub.7 cycloalkyl, C.sub.5 -C.sub.7 cycloalkenyl and C.sub.6 -C.sub.10 aryl, wherein any member of said R.sup.3, except H, is optionally substituted with one to two substituents independently selected from the group consisting of --OR.sup.2, --C(O)--NH--R.sup.2, --S(O)--N(R.sup.2) (R.sup.2), Ht, --CN, --SR.sup.2, --CO.sub.2 R.sup.2, and NR.sup.2 --C(O)--R.sup.2 ;

each n is independently 1 or 2;

D and D' are independently selected from the group consisting of R.sup.7 ; C.sub.1 -C.sub.4 alkyl substituted with C.sub.3 -C.sub.6 cycloalkyl, --O--R.sup.7 or R.sup.7, and optionally substituted with one additional substituent selected from C.sub.3 -C.sub.6 cycloalkyl, --O--R.sup.7 --, R.sup.7, OR.sup.2 or --R.sup.3 ; C.sub.2 -C.sub.4 alkenyl substituted with C.sub.3 -C.sub.6 cycloalkyl, --O--R.sup.7 or R.sup.7, and optionally substituted with one additional substituent selected from C.sub.3 -C.sub.6 cycloalkyl, --O--R.sup.7 --, R.sup.7, OR.sup.2 or --R.sup.3 ; C.sub.3 -C.sub.6 cycloalkyl, which is optionally substituted with or fused with R.sup.7 ; and C.sub.5 -C.sub.6 cycloalkenyl, which is optionally substituted with or fused with R.sup.7 ;

each R.sup.7 is independently selected from the group consisting of phenyl and a 3-6 membered carbocyclic ring, wherein said carbocyclic ring may be saturated or unsaturated and wherein R.sup.7 is optionally substituted with one to two groups independently selected from the group consisting of oxo, --OR.sup.2, --R.sup.2, --N(R.sup.2) (R.sup.2), --N(R.sup.2)--C(O)--R.sup.2, C.sub.1 -C.sub.3 alkyl substituted with --OH and optionally substituted with R.sup.7, --CN, --CO.sub.2 R.sup.2, --C(O)--N(R.sup.2) (R.sup.2), halo and --CF.sub.3 ;

E is selected from the group consisting of Ht.sub.E ; O--Ht.sub.E ; Ht.sub.E --Ht.sub.E ; --O--R.sup.3 substituted with Ht.sub.E, --NR.sup.2 R.sup.3 substituted with Ht.sub.E, C.sub.1 -C.sub.6 alkyl substituted with Ht.sub.E, and C.sub.2 -C.sub.6 alkenyl substituted with Ht.sub.E, wherein the substituted --O--R.sup.3, --NR.sup.2 R.sup.3 or C.sub.1 -C.sub.6 alkyl is optionally substituted with one additional substituent selected from the group consisting of R.sup.4 and Ht.sub.E ; C.sub.3 -C.sub.6 saturated carbocycle, which is optionally substituted with one to two groups independently selected from the group consisting of R.sup.4 and Ht.sub.E ; and C.sub.5 -C.sub.6 unsaturated carbocycle, which is optionally substituted with one to two groups independently selected from the group consisting of R.sup.4 and Ht.sub.E ;

wherein each Ht.sub.E is independently selected from the group consisting of C.sub.3 -C.sub.7 cycloalkyl; C.sub.5 -C.sub.7 cycloalkenyl; or C.sub.6 --C.sub.10 aryl; wherein Ht.sub.E is optionally substituted with one or two substituents independently selected from the group consisting of oxo, --OR.sup.2, --R.sup.2, --N(R.sup.2) (R.sup.2), --R.sup.2 --OH, --CN, --CO.sub.2 R.sup.2, --C(O)--N(R.sup.2) (R.sup.2), --S(O).sub.2 --N(R.sup.2) (R.sup.2), --N(R.sup.2)--C(O)--R.sub.2, --C(O)--R.sup.2, --S(O).sub.n --R.sup.2, --OCF.sub.3, --S(O).sub.n --R.sup.7, methylenedioxy, --N(R.sup.2)--S(O).sub.2 (R.sup.2), halo, --CF.sub.3, --NO.sub.2, R.sup.7 and --O--R.sup.7 ; and

each R.sup.4 is independently selected from the group consisting of --OR.sup.2, --C(O)--NHR.sup.2, --S(O).sub.2 --NHR.sup.2, halo, --NR.sup.2 --C(O)--R.sup.2 and --CN.

2. The compound according to claim 1, wherein said compound has the structure of formula XXII: ##STR612##

wherein A, D' and E are defined as in claim 1.

3. The compound according to claim 1, wherein said compound has the structure of formula XXIII: ##STR613##

wherein x, Ht, R.sup.3, D' and E are defined as in claim 1.

4. A compound of formula I, wherein:

A is selected from the group consisting of --R.sup.1 --Ht; --R.sup.1 --C.sub.1 -C.sub.6 alkyl substituted with Ht or --O--Ht and optionally substituted with one additional substituent selected from the group consisting of hydroxy, C.sub.1 -C.sub.4 alkoxy, Ht, and --O--Ht; and --R.sup.1 --C.sub.2 -C.sub.6 alkenyl substituted with Ht or --O--Ht and optionally substituted with one additional substituent selected from hydroxy, C.sub.1 -C.sub.4 alkoxy, Ht or --O--Ht;

each R.sup.1 is independently selected from the group consisting of --C(O)--, --S(O).sub.2 --, --C(O)--C(O)--, --O--CO--, --O--S(O).sub.2 -- and --NR.sup.2 --S(O).sub.2 --;

each Ht is a 5-membered nitrogen-containing saturated or unsaturated heterocycle, optionally containing one additional heteroatom selected from N or O, which is optionally benzofused; and wherein Ht is optionally substituted with one to two substituents independently selected from the group consisting of oxo, --OR.sup.2, --R.sup.2, --N(R.sup.2).sub.2, --R.sup.2 --OH, --CN, --CO.sub.2 R.sup.2, --C(O)--N(R.sup.2).sub.2 and --S(O).sub.2 --N(R.sup.2).sub.2 ;

each R.sup.2 is independently selected from the group consisting of H and C.sub.1 -C.sub.3 alkyl;

B, when present, is --NH--CH(R.sup.3)--C(O)--;

x is 0 or 1;

R.sup.3 is selected from the group consisting of Ht, C.sub.1 -C.sub.6 alkyl, C.sub.2 -C.sub.6 alkenyl, C.sub.3 -C.sub.7 cycloalkyl, C.sub.5 -C.sub.7 cycloalkenyl and C.sub.6 -C.sub.10 aryl, wherein any member of said R.sup.3 is optionally substituted with one to two substituents independently selected from the group consisting of --OR.sup.2, --C(O)--NH--R.sup.2, --S(O).sub.n --N(R.sup.2).sub.2, Ht and --CN;

n is 1 or 2;

D and D' are independently selected from the group consisting of R.sup.7 ; C.sub.1 -C.sub.4 alkyl substituted with C.sub.3 -C.sub.6 cycloalkyl or R.sup.7 ; C.sub.2 -C.sub.4 alkenyl substituted with C.sub.3 -C.sub.6 cycloalkyl or R.sup.7 ; C.sub.3 -C.sub.6 cycloalkyl, optionally substituted with or fused with R.sup.7 ; and C.sub.5 -C.sub.6 cycloalkenyl, optionally substituted with or fused with R.sup.7 ;

R.sup.7 is selected from the group consisting of phenyl; and 3-6 membered carbocyclic ring, wherein said carbocyclic ring may be saturated or unsaturated and R.sup.7 is optionally substituted with one to two groups independently selected from the group consisting of oxo, --OR.sup.2, --R.sup.2, --N(R.sup.2).sub.2, --N(R.sup.2)--C(O)R.sup.2, C.sub.1 -C.sub.3 alkyl substituted with --OH and optionally substituted with R.sup.7, --CN, --CO.sub.2 R.sup.2, --C(O)--N(R.sup.2).sub.2, halo and --CF.sub.3 ;

E is selected from the group consisting of Ht.sub.E ; --O--R.sup.3 substituted with Ht.sub.E, --NR.sup.2 R.sup.3 substituted with Ht.sub.E, and C.sub.1 -C.sub.6 alkyl substituted with Ht.sub.E, wherein the substituted --O--R.sup.3, --NR.sup.2 R.sup.3 or C.sub.1 -C.sub.6 alkyl is optionally substituted with one additional substituent selected from the group consisting of R.sup.4 and Ht.sub.E ; C.sub.3 -C.sub.6 saturated carbocycle, which is optionally substituted with one to two groups independently selected from the group consisting of R.sup.4 and Ht.sub.E ; and C.sub.5 -C.sub.6 unsaturated carbocycle, which is optionally substituted with one to two groups independently selected from the group consisting of R.sup.4 and Ht.sub.E ;

each R.sup.4 is independently selected from the group consisting of --OR.sup.2, --C(O)--NHR.sup.2, --S(O).sub.2 --NHR.sup.2, halo and --CN; and

each R.sup.5 is independently selected from the group consisting of H and R.sup.3.

5. The compound according to claim 2, wherein:

A is R.sup.1 --Ht; and

D' is selected from the group consisting of C.sub.1 -C.sub.3 alkyl and C.sub.3 alkenyl, wherein said alkyl or alkenyl may optionally be substituted with one to two groups selected from the group consisting of C.sub.3 -C.sub.6 cycloalkyl, --OR.sup.2, --O--R.sup.7 and R.sup.7.

6. The compound according to claim 3, wherein:

R.sup.3 is selected from the group consisting of C.sub.1 -C.sub.6 alkyl, C.sub.2 -C.sub.6 alkenyl, C.sub.5 -C.sub.6 cycloalkyl and C.sub.5 -C.sub.6 cycloalkenyl, wherein any member of said R.sup.3 is optionally substituted with one to two substituents independently selected from the group consisting of --OR.sup.2, --C(O)--NH--R.sup.2, --S(O).sub.n N(R.sub.2) (R.sup.2), Ht, --CN, --SR.sup.2, --C(O).sub.2 R.sup.2, NR.sup.2 --C(O)--R.sup.2 ; and

D' is selected from the group consisting of C.sub.1 -C.sub.3 alkyl and C.sub.3 alkenyl, wherein said alkyl or alkenyl is substituted with C.sub.3 -C.sub.6 cycloalkyl, --O--R.sup.7 or R.sup.7 and additionally substituted with one additional substituent selected from C.sub.3 -C.sub.6 cycloalkyl, --OR.sup.2, --O--R.sup.7 or R.sup.7.

7. The compound according to claim 1, wherein said compound has a molecular weight less than or equal to about 700 g/mol.

8. A compound according to claim 7, wherein said compound has a molecular weight less than or equal to about 600 g/mol.

9. A pharmaceutical composition comprising a pharmaceutically effective amount of a compound according to any one of claims 1-3 and a pharmaceutically acceptable carrier, adjuvant or vehicle.

10. The compound according to claim 2, wherein A is R.sup.1 --Ht and wherein R.sup.1 and Ht are defined as in claim 1.

11. The compound according to claim 10, wherein D' is selected from the group consisting of C.sub.1 -C.sub.4 alkyl and C.sub.1 alkyl substituted with C.sub.3 -C.sub.6 cycloalkyl.

12. The compound according to claim 10, wherein:

R.sup.1 is --O--C(O)--;

each Ht is independently selected from the group consisting of 5-7 membered saturated or unsaturated heterocycle, containing one or more heteroatoms selected from N, N(R.sup.2), O, S and S(O).sub.n, wherein said heterocycle may optionally be benzofused; and wherein any member of said Ht may be optionally substituted with one to two substituents selected from the group consisting of oxo, --OR.sup.2, --R.sup.2, --N(R.sup.2) (R.sup.2), --R.sup.2 --OH, --CN, --CO.sub.2 R.sup.2, --C(O)--N(R.sup.2) (R.sup.2), --S(O).sub.2 --N(R.sup.2) (R.sup.2), --N(R.sup.2)--C(O)--R.sub.2, --C(O)--R.sup.2, --S(O).sub.n --R.sup.2, --OCF.sub.3, --S(O).sub.n --R.sup.7, methylenedioxy, --N(R.sup.2)--S(O).sub.2 (R.sup.2), halo, --CF.sub.3, --NO.sub.2, R.sup.7 and --O--R.sup.7 ;

each D' is independently selected from the group consisting of C.sub.1 -C.sub.4 alkyl, which may be optionally substituted with one to two groups selected from C.sub.3 -C.sub.6 cycloalkyl, --OR.sub.2, --R.sup.3, --O--R.sup.7 and R.sup.7 ; C.sub.2 -C.sub.4 alkenyl, which may be optionally substituted with one to two groups selected from the group consisting of C.sub.3 -C.sub.6 cycloalkyl, --OR.sup.2, --R.sup.3, --O--R.sup.7 and R.sup.7 ; C.sub.3 -C.sub.6 cycloalkyl, which may be optionally substituted with or fused with R.sup.7 ; and C.sub.5 -C.sub.6 cycloalkenyl, which may be optionally substituted with or fused with R.sup.7 ; and

E is selected from the group consisting of C.sub.3 -C.sub.7 cycloalkyl; C.sub.5 -C.sub.7 cycloalkenyl; C.sub.8 -C.sub.10 aryl; and 5-7 membered saturated or unsaturated heterocycle, containing one or more heteroatoms selected from N, N(R.sup.2), O, S and S(O).sub.n, wherein said heterocycle may optionally be benzofused; and wherein any member of said Ht may be optionally substituted with one to two substituents selected from the group consisting of oxo, --OR.sup.2, --R.sup.2, --N(R.sup.2) (R.sup.2), --R.sup.2 --OH, --CN, --CO.sub.2 R.sup.2, --C(O)--N(R.sup.2) (R.sup.2), --S(O).sub.2 --N(R.sup.2) (R.sup.2), --N(R.sup.2)--C(O)--R.sub.2, --C(O)--R.sup.2, --S(O).sub.n --R.sup.2, --OCF.sub.3, --S(O).sub.n --R.sup.7, methylenedioxy, --N(R.sup.2)--S(O).sub.2 (R.sup.2), halo, --CF.sub.3, --NO.sub.2, R.sup.7 and --O--R.sup.7.

13. The compound according to claim 10, wherein said compound is: ##STR614##

4-methoxy-N-((2 syn,3S)-2-hydroxy-4-phenyl-3-((R)-pyrrolidin-3-yloxycarbonylamino)-butyl)- N-cyclopentylmethylbenzenesulfonamide HCl salt.
« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

How are People Using DrugPatentWatch?

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

`abc